p21 Antikörper

Produktnummer ABIN967445

Produktdetails anti-p21 Antikörper

Target: p21 (CDKN1A) (Cyclin-Dependent Kinase Inhibitor 1A (p21, Cip1) (CDKN1A))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser p21 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunoprecipitation (IP), Immunohistochemistry (Frozen Sections) (IHC (fro))

Marke: BD Pharmingen™

Produktmerkmale: 1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Please refer to us for technical protocols.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.

Aufreinigung: The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

Immunogen: Human p21

Klon: 6B6

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: Applications include immunoprecipitation (1-2 µg/1x10^6 cells), western blot analysis (1-2 µg/ml) and immunohistochemistry of paraformaldehyde-fixed cultured cells (0.5-2.5 µg/ml) and acetone-fixed, frozen and formalin-fixed paraffin-embedded (10 µg/ml) tissue sections. MCF7 human breast carcinoma cells (ATCC HTB-22) are suggested as a positive control. WI-38 human lung fibroblasts (ATCC CCL-75) treated with doxorubin (Adriamycin) can also be used as a positive control.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 0.5 mg/mL

Buffer: Aqueous buffered solution containing ≤0.09 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C

Informationen zur Lagerung: Store undiluted at 4°C.

Referenzen für anti-p21 Antikörper (ABIN967445)

Clarke, Lotz, Chao, Mercurio: "Activation of the p21 pathway of growth arrest and apoptosis by the beta 4 integrin cytoplasmic domain." in: The Journal of biological chemistry, Vol. 270, Issue 39, pp. 22673-6, (1995) (PubMed).

Halevy, Novitch, Spicer, Skapek, Rhee, Hannon, Beach, Lassar: "Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD." in: Science (New York, N.Y.), Vol. 267, Issue 5200, pp. 1018-21, (1995) (PubMed).

el-Deiry, Harper, OConnor, Velculescu, Canman, Jackman, Pietenpol, Burrell, Hill, Wang: "WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis." in: Cancer research, Vol. 54, Issue 5, pp. 1169-74, (1994) (PubMed).

Hunter: "Braking the cycle." in: Cell, Vol. 75, Issue 5, pp. 839-41, (1994) (PubMed).

Noda, Ning, Venable, Pereira-Smith, Smith: "Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen." in: Experimental cell research, Vol. 211, Issue 1, pp. 90-8, (1994) (PubMed).

Xiong, Hannon, Zhang, Casso, Kobayashi, Beach: "p21 is a universal inhibitor of cyclin kinases." in: Nature, Vol. 366, Issue 6456, pp. 701-4, (1994) (PubMed).

el-Deiry, Tokino, Velculescu, Levy, Parsons, Trent, Lin, Mercer, Kinzler, Vogelstein: "WAF1, a potential mediator of p53 tumor suppression." in: Cell, Vol. 75, Issue 4, pp. 817-25, (1993) (PubMed).

Details zu p21

Target: p21 (CDKN1A) (Cyclin-Dependent Kinase Inhibitor 1A (p21, Cip1) (CDKN1A))

Andere Bezeichnung: p21 (CDKN1A Produkte)

Synonyme: CCND1 antikoerper, CDKN1A antikoerper, CAP20 antikoerper, CDKN1 antikoerper, CIP1 antikoerper, MDA-6 antikoerper, P21 antikoerper, SDI1 antikoerper, WAF1 antikoerper, p21CIP1 antikoerper, CDKI antikoerper, Cdkn1 antikoerper, Waf1 antikoerper, mda6 antikoerper, p21Cip1 antikoerper, p21WAF antikoerper, Cip1 antikoerper, UV96 antikoerper, p21 antikoerper, cip1 antikoerper, p16Xic2 antikoerper, sdi1 antikoerper, waf1 antikoerper, cap20 antikoerper, cdkn1 antikoerper, mda-6 antikoerper, p21cip1 antikoerper, si:ch1073-48m5.2 antikoerper, KRAS2 antikoerper, p21ras antikoerper, cyclin D1 antikoerper, cyclin dependent kinase inhibitor 1A antikoerper, cyclin-dependent kinase inhibitor 1A (P21) antikoerper, cyclin-dependent kinase inhibitor 1A antikoerper, cyclin-dependent kinase inhibitor 1A L homeolog antikoerper, cyclin-dependent kinase inhibitor 1 antikoerper, KRAS proto-oncogene, GTPase antikoerper, CCND1 antikoerper, CDKN1A antikoerper, Cdkn1a antikoerper, cdkn1a.L antikoerper, cki1 antikoerper, cdkn1a antikoerper, KRAS antikoerper

Hintergrund: P21 belongs to a class of tumor suppressors including p16 and p27 which control progression through the cell cycle by inhibiting the activity of cyclin-cdk complexes. p21 is also known as senescent cell-derived inhibitor 1 (Sdi1), wild-type p53-activated fragment 1 (Waf1), Cdk-interacting protein 1 (Cip1), p21 and p53-regulated inhibitor of Cdks (Pic1). p21 mRNA is expressed at higher levels in senescent fibroblasts than in actively growing cells. When introduced into proliferating foreskin fibroblasts, p21 inhibits DNA synthesis and cell cycle arrest. p53 can activate p21 gene expression via a p53 binding site identified in the promoter of the p21 gene.

Molekulargewicht: 21 kDa

Pathways: p53 Signalweg, PI3K-Akt Signalweg, Zellzyklus, AMPK Signaling, Fc-epsilon Rezeptor Signalübertragung, EGFR Signaling Pathway, Neurotrophin Signalübertragung, Mitotic G1-G1/S Phases, DNA Replication, Hepatitis C, Synthesis of DNA, Autophagie